Credevo

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Credevo, Health/Medical/ Pharmaceuticals, Singapore.

A global Clinical Trial Organization (CTO) providing comprehensive clinical trial services for pharmaceuticals, biologics, medical devices and healthcare products Credevo provides strategic support for healthcare products including;

- Drugs

- Biologics

- Health Supplements (Nutraceuticals)

- IVD and medical devices

- Cosmetics

In areas of

- Regulatory

- Clinical Development

- Business Development Support

- Licensing (out-/in-)

- Feasibility

19/06/2026

A generic company had a standard crossover design ready for a BA/BE study. The design needed to change before anyone enrolled.

The compound was a modified-release formulation. Standard crossover parameters are built for immediate-release drugs. Washout periods, PK sampling schedules. For modified-release, the drug absorbs and clears differently. A template designed for immediate-release applied here won't produce PK data that reliably supports a bioequivalence conclusion.

Caught during protocol review, before first patient. The crossover stayed. Washout extended, sampling schedule rebuilt, eligibility criteria adjusted.

Cost before enrollment: one week of protocol revision. Cost mid-study: a full amendment, delayed database lock, and a potential FDA query at submission.

BA/BE studies look routine until the formulation isn't.

What FDA BE study requirements look like in practice, including where formulation-specific design changes the outcome: https://credevo.com/articles/2025/06/15/ba-be-study-requirements-for-fda-approval-guidelines-global-locations-costs-quality-standards/

If you want a design review before protocol finalisation, we're here: https://credevo.com/contact

18/06/2026

A sponsor building APAC clinical capability for the first time usually comes in with SOPs designed for somewhere else.

The US and EU frameworks are in the documentation. What's missing is the APAC layer. Country-specific regulatory requirements, local IRB processes, monitoring expectations in Thailand, India, or Malaysia. A CRO that applies the sponsor's global SOPs without flagging the gaps creates compliance risk without naming it.

What works is a review before the first site opens. Which parts apply to the APAC context directly? Where does a country-specific supplement need to be written? Where is the CRO operating under its own SOPs with documented sponsor agreement? What triggers a review when something changes?

This doesn't need to add weeks to startup. It needs to happen before ex*****on begins.

What a QMS framework looks like in APAC practice, including what global SOPs typically miss: https://credevo.com/articles/2025/03/15/quality-by-design-in-clinical-trials-building-maintaining-a-qms-framework/

If the SOP integration hasn't been fully worked through for your first APAC study, we're here: https://credevo.com/contact

17/06/2026

Japan has one of the most rigorous regulatory environments for clinical trials in the world. Sponsors who have worked there will tell you the rigour is the feature, not the problem.

PMDA review is detailed and query-heavy. A foreign sponsor cannot act as the local sponsor in Japan. An In-Country Clinical Coordinator is required and manages the regulatory interface between the sponsor and PMDA. Getting this function right matters more than most sponsors realise before they start.

The language runs through everything. Documents, site visits, query responses. A CRO without embedded Japanese capability is managing a translation layer on top of an already demanding process.

Site relationships matter here differently from most other APAC markets. Investigator continuity is expected. A CRO that understands Japanese investigator culture comes in differently from one that adjusts as it goes.

Credevo provides the In-Country Clinical Coordinator function, manages Japanese-language regulatory submissions, and runs full-service Phase II to IV studies in Japan.

We've covered what PMDA timelines look like in practice and what sponsors working in Japan for the first time need to prepare: https://credevo.com/articles/2024/10/25/top-7-reasons-to-choose-japan-for-your-clinical-trials/

If Japan is in your development program and you want a practical view of what ex*****on involves, we're here: https://credevo.com/contact

16/06/2026

Most APAC clinical trial content describes the region from the outside. Country maps, framework tables, patient population data. Useful for orientation. Not useful for planning ex*****on.

The difference between knowing APAC from a database and knowing it from working in it shows up in specific moments: which investigator to call at a particular site, whether a regulatory query needs a new document or a re-explanation of what was submitted, whether a site's track record in a specific indication is still current.

None of that is in a framework document. It's in the people who have built relationships with these sites and investigators, and seen the regulatory process from the inside.

Credevo is headquartered in Singapore. Our teams are embedded across Thailand, Malaysia, India, Sri Lanka, and extended APAC. The knowledge we apply to feasibility and ex*****on comes from working in these markets, not from a regional summary.

We've written about what investigators and sites in APAC actually look like in practice: https://credevo.com/articles/2023/10/15/clinical-trial-investigators-sites-in-the-asia-pacific-region/

If you're planning an APAC study and want a view grounded in current, on-ground experience, we're here: https://credevo.com/contact

15/06/2026

A study can run correctly and still fail. If the endpoint wasn't designed to detect what the product actually does, the result was set before enrollment began.

Clinical relevance and operational detectability aren't the same thing. An endpoint that makes scientific sense may still require measurements that site staff apply inconsistently, or assume an effect size the available population can't produce. A sample size calculation that depends on assumptions that don't hold in ex*****on will leave the study underpowered regardless of how well it runs.

An estimated 50 percent of clinical trials fail to meet their primary endpoints. Many of those failures trace back to design decisions made before the first patient enrolled.

Credevo advises on endpoint selection, sample size assumptions, and operational definitions before protocols are locked. The point is to build the study around what it can actually deliver.

We've written about what planning looks like when study design is built to succeed: https://credevo.com/articles/2024/06/15/strategic-approaches-to-clinical-trial-planning-ensuring-success-from-design-to-ex*****on/

If your endpoint choices haven't been tested against what your available sites can do, we're here: https://credevo.com/contact

12/06/2026

Selective Phase I studies in APAC are not a shortcut to IND approval. They're a strategic choice about where to generate your first-in-human safety data.

Australia, India, and other APAC markets each have defined pathways for early-phase research. Which one fits depends on the asset, the regulatory strategy, and how the data will eventually be used.

What makes a Phase I work is not just the pathway. It's investigators with early-phase experience, sites with clinical pharmacology infrastructure, and safety oversight that can respond to FIH data in real time.

Credevo runs selective Phase I and First-in-Human studies across APAC and the United States, advising on market selection and managing regulatory approval through to study completion.

We've covered what sponsors need to prepare before the first dose is administered. https://credevo.com/articles/2025/01/05/first-in-human-fih-clinical-trials-key-considerations-for-sponsors/

If you're planning a Phase I study and want a grounded view on the right market and approach, we're here: https://credevo.com/contact

11/06/2026

The sponsor ruled out a market before feasibility started. Feasibility put it back.

Phase II, metabolic indication. Two markets in the plan. A third ruled out because the approval process "sounded slow."

Feasibility showed a different picture. A regulatory pathway for this indication running faster than both original markets, not because of a rule change, but because of where study volume sat and how competitive the indication was at that point in the review window.

The sponsor added the market. Regulatory approval came in before the other two. First patient enrolled there first.

Regulatory reputation by country is a starting point. Current-state feasibility is what you plan around.

We've covered what regulatory feasibility actually involves and how it changes country selection: https://credevo.com/articles/2024/12/15/regulatory-feasibility-assessment-in-clinical-trials-need-and-impact/

If you're finalising a country list and want to pressure-test it, we're here: https://credevo.com/contact

10/06/2026

A company developing an in vitro diagnostic doesn't always need enrolled patients to validate its device.

If residual samples from existing clinical workflows are appropriate, there's no recruitment, no site network, no enrolment timeline. That changes the cost, the timeline, and the regulatory pathway significantly.

Whether residual samples work depends on the device's intended use, the performance claims, and the regulatory pathway being pursued. In some cases a prospective study is necessary. In others, it isn't. Getting this right before committing to a design saves time that's hard to recover.

Credevo runs medical device studies across APAC and the United States, including IVD performance studies and device evaluation studies. Where the study type isn't determined, we advise on the right design first.

If you're developing a medical device and want to understand what study type the validation objective requires, we're here: https://credevo.com/contact

09/06/2026

An APAC oncology trial doesn't start when the first patient is enrolled. It starts about 10 months before that.

Regulatory submissions in each country run in parallel. IRB approvals happen on country-specific schedules. Databases need to be built and validated. Sites complete initiation visits before they can see a patient. Each step has a dependency.

What changes the outcome isn't speed. It's whether the team has run this process in these specific markets before. In Thailand, a well-prepared CTA moves differently from one with documentation gaps. In India, CDSCO oncology queries follow patterns experienced teams know. In South Korea, the MFDS review has its own rhythm.

The study isn't starting in one place. It's starting in four at once.

Credevo manages full-service Phase II and III oncology trials across APAC and the United States, with startup managed centrally from Singapore.

We've written about what makes APAC the right environment for oncology research, including what affects startup timelines: https://credevo.com/articles/2023/12/05/clinical-trials-in-oncology-why-asia-pac-stands-out-as-the-destination-of-choice/
If you're planning an oncology study in APAC, we're here: https://credevo.com/contact

08/06/2026

The regulatory timeline in the guidance document is not the timeline your study will run on.

Every APAC country has a published framework. What the frameworks don't describe: query response times in practice, current review backlogs, documentation gaps most commonly flagged, which markets are running faster or slower right now.

Sponsors working off published timelines instead of current on-ground experience pay for that gap in delays they didn't plan for.

We've covered what clinical operations in APAC actually look like, including country-specific challenges: https://credevo.com/articles/2025/08/15/mastering-clinical-operations-in-asia-pacific-overcoming-challenges-with-smart-solutions/
If you're building a timeline for a study in Malaysia, Thailand, India, or Sri Lanka, we can share what we're currently seeing: https://credevo.com/contact

Address

Singapore

Website

https://credevo.com/

Alerts

Be the first to know and let us send you an email when Credevo posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your business to be the top-listed Health & Beauty Business in Singapore?